ZOETIS INC
ZTSNYSETrading Snapshot
- Day Range
- $69.56 β $71.76
- 52-Week Range
- $69.52 β $148.79
- Volume
- $2.90B
- Avg Volume
- $2.86B
- Shares Outstanding
- 419.2M
- Next Earnings
- Nov 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $9.47B
- Last Q Revenue
- $2.47B
- P/E Ratio
- 11.7
- P/S Ratio
- 3.1x
- EPS (TTM)
- $6.26
- Dividend Yield
- 2.93%
- Dilution (1yr)
- β2.8%
Why Investors Own ZTS
- βHigh-growth profile β revenue up +54.7% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ZOETIS INC
ZTSAbout ZOETIS INC
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive

Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.

Zoetis: The Worst May Be Priced In
Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but internationa

Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in d

Zoetis: An Undervalued Compounder Hiding In Plain Sight
Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin